Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonio Jimeno

Showing results (1-10 of 246) with videos related to

Pageof 25
Sort By:
Future Oncology (London, England)|March 25, 2006
Race, gender and mutations in the prediction of anti-EGFR activityAntonio Jimeno
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Eribulin: rediscovering tubulin as an anticancer targetAntonio Jimeno
Journal of Biomedical Informatics|August 12, 2017
Word embeddings and recurrent neural networks based on Long-Short Term Memory nodes in supervised biomedical word sense disambiguationAntonio Jimeno Yepes
Molecular Cancer Therapeutics|May 2, 2006
Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancerAntonio Jimeno, Manuel Hidalgo
Critical Reviews in Oncology/Hematology|July 18, 2006
Multitargeted therapy: can promiscuity be praised in an era of political correctness?Antonio Jimeno, Manuel Hidalgo
Drugs of Today (Barcelona, Spain : 1998)|June 28, 2006
Atrasentan: a rationally designed targeted therapy for cancerAntonio Jimeno, Michael Carducci
Expert Review of Anticancer Therapy|August 23, 2005
Promises and pitfalls in the prediction of antiepidermal growth factor receptor activityAntonio Jimeno, Manuel Hidalgo
Pharmacology & Therapeutics|December 23, 2017
Bispecific antibodies for cancer therapy: A reviewAnuradha Krishnamurthy, Antonio Jimeno
Expert Opinion on Investigational Drugs|November 30, 2004
Atrasentan: targeting the endothelin axis in prostate cancerAntonio Jimeno, Michael Carducci
Biochimica Et Biophysica Acta|October 19, 2006
Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitorsAntonio Jimeno, Manuel Hidalgo
Pageof 25

Showing results (1-10 of 246) with videos related to

Sort By:
Pageof 25
Future Oncology (London, England)|March 25, 2006
Race, gender and mutations in the prediction of anti-EGFR activityAntonio Jimeno
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2009
Eribulin: rediscovering tubulin as an anticancer targetAntonio Jimeno
Journal of Biomedical Informatics|August 12, 2017
Word embeddings and recurrent neural networks based on Long-Short Term Memory nodes in supervised biomedical word sense disambiguationAntonio Jimeno Yepes
Molecular Cancer Therapeutics|May 2, 2006
Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancerAntonio Jimeno, Manuel Hidalgo
Critical Reviews in Oncology/Hematology|July 18, 2006
Multitargeted therapy: can promiscuity be praised in an era of political correctness?Antonio Jimeno, Manuel Hidalgo
Drugs of Today (Barcelona, Spain : 1998)|June 28, 2006
Atrasentan: a rationally designed targeted therapy for cancerAntonio Jimeno, Michael Carducci
Expert Review of Anticancer Therapy|August 23, 2005
Promises and pitfalls in the prediction of antiepidermal growth factor receptor activityAntonio Jimeno, Manuel Hidalgo
Pharmacology & Therapeutics|December 23, 2017
Bispecific antibodies for cancer therapy: A reviewAnuradha Krishnamurthy, Antonio Jimeno
Expert Opinion on Investigational Drugs|November 30, 2004
Atrasentan: targeting the endothelin axis in prostate cancerAntonio Jimeno, Michael Carducci
Biochimica Et Biophysica Acta|October 19, 2006
Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitorsAntonio Jimeno, Manuel Hidalgo
Pageof 25